Lactic acid bacteria with hypoglycemic function and application thereof

Abstract

The present application relates to lactic acid bacteria with blood sugar lowering function and application thereof, and particularly provides a group of lactic acid bacteria with high safety, which can play an important role in regulating intestinal microecological balance of human body and has blood sugar lowering effect.The lactic acid bacteria is named as Lactobacillus johnsonii 4437-4AT, the strain number is 4437-4AT, and was preserved in Guangdong Microbial Culture Collection Center on January 20, 2026, the preservation address is: No. 59 Building, 5th Floor, Guangzhou Xianlie Middle Road 100 Courtyard, the preservation number is: GDMCC NO: 67710.

Description

Technical Field

[0001] This invention belongs to the field of microbial technology and functional foods, specifically involving lactic acid bacteria strains isolated and screened from animal feces that have significant inhibitory activity on α-amylase and α-glucosidase, and their application in products related to regulating blood sugar and preventing or adjuvant treatment of hyperglycemia. Background Technology

[0002] Hyperglycemia and diabetes are common metabolic diseases worldwide. Existing drugs, such as alpha-glucosidase inhibitors (e.g., acarbose), often have side effects such as gastrointestinal discomfort. Probiotics, by inhibiting the activity of intestinal carbohydrate-digesting enzymes, can serve as a natural and safe adjunctive method for lowering blood sugar. However, current probiotic strains still have shortcomings in terms of blood sugar-lowering efficiency, enzyme inhibition specificity, and gastrointestinal tolerance. There is an urgent need to screen for new lactic acid bacteria strains with highly efficient and stable blood sugar-lowering functions. Summary of the Invention

[0003] The present invention aims to overcome the above-mentioned defects and provide a group of lactic acid bacteria that have high safety, play an important role in regulating the balance of human intestinal microecology, and have the effects of lowering blood lipids and blood sugar.

[0004] This invention provides a lactic acid bacterium with hypoglycemic function, characterized in that: the lactic acid bacterium is named Lactobacillus johnsonii 4437-4AT, strain number 4437-4AT, and was deposited on January 20, 2026 at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67710.

[0005] This invention also suggests the application of the above-mentioned lactic acid bacteria in the preparation of hypoglycemic products.

[0006] This invention also suggests the application of the above-mentioned lactic acid bacteria in the preparation of products that regulate the balance of human intestinal microecology.

[0007] In addition, the present invention provides a microbial preparation comprising the above-mentioned lactic acid bacteria, fermentation supernatant of lactic acid bacteria, bacterial extract of lactic acid bacteria, or freeze-dried lactic acid bacteria powder.

[0008] This invention also suggests the use of the above-mentioned microbial preparations in the preparation of functional products for inhibiting α-amylase and / or α-glucosidase.

[0009] This invention also suggests the application of the above-mentioned microbial preparations in the preparation of foods, health products or drugs that have the function of lowering blood sugar or assisting in regulating postprandial blood sugar.

[0010] The products mentioned above can be pharmaceuticals, foods (such as dairy products and non-dairy fermented products), dietary supplements (such as probiotic powders, capsules, tablets, and compound products combined with prebiotics, etc.).

[0011] The function and effects of this invention:

[0012] The strain of the present invention has an inhibition rate of not less than 40% against α-amylase, preferably up to 54.60%;

[0013] The strain of the present invention exhibits an inhibition rate of not less than 30% against α-glucosidase, preferably up to 31.33%;

[0014] The strains of this invention have good acid and bile salt resistance and can survive and maintain function in a simulated gastrointestinal environment;

[0015] The strains of this invention are sensitive to antibiotics and meet food safety requirements. Attached Figure Description

[0016] Figure 1 Results of the acid-producing capacity of ten isolated strains;

[0017] Figure 2 , five Comparison of the α-amylase inhibitory abilities of strains of lactic acid bacteria;

[0018] Figure 3 Comparison of the α-glucosidase inhibitory abilities of five lactic acid bacteria strains;

[0019] Figure 4 Comparison of growth curves of five lactic acid bacteria strains;

[0020] Figure 5 Comparison of the acid and bile salt tolerance of five strains of lactic acid bacteria;

[0021] Figure 6 Comparison of the surface hydrophobicity of five lactic acid bacteria strains;

[0022] Figure 7 Comparison of the self-aggregation properties of five strains of lactic acid bacteria;

[0023] Figure 8 Morphological identification results of .4437-4AT;

[0024] Figure 9 Results of hemolysis test for .4437-4AT. Detailed Implementation

[0025] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0026] Example 1. Screening of animal-derived lactic acid bacteria

[0027] 1.1 Materials and Methods

[0028] 1.1.1. Main Reagents and Instruments

[0029] Sodium taurine deoxycholate was purchased from Shanghai E-En Chemical Technology Co., Ltd.; glycine was purchased from neoFroxx GmbH, Germany; sodium glycocholate was purchased from Shanghai Shifeng Biotechnology Co., Ltd.; ninhydrin hydrate and ferric ammonium sulfate were purchased from Shanghai Maclean Biochemical Technology Co., Ltd.; α-amylase (pig pancreas), α-glucosidase and PNPG p-nitrophenyl-BD-glucopyranoside were purchased from Shanghai Yuanye Biotechnology Co., Ltd.; bovine bile salts were purchased from Biotopped Beijing Biotop Technology Co., Ltd.; xylene was purchased from Xilong Scientific Co., Ltd.; total antioxidant capacity (T-AOC) assay kit was purchased from Beijing Solarbio Technology Co., Ltd.; DPPH scavenging capacity assay kit, hydroxyl radical scavenging rate assay kit and TCA trichloroacetic acid were purchased from Beijing Regen Biotechnology Co., Ltd.; blood agar plates and drug sensitivity test strips were purchased from Bikman Biotechnology Co., Ltd., and the drug sensitivity test strips were for: penicillin (10 μg / tablet), oxacillin (1 μg / tablet), ampicillin (10 μg / tablet), piperacillin ( 100μg / tablet), cephalexin (30μg / tablet), cefazolin (30μg / tablet), cefuroxime sodium (30μg / tablet), ceftazidime (30μg / tablet), ceftriaxone (30μg / tablet), cefoperazone (75μg / tablet), amikacin (30μg / tablet), gentamicin (10μg / tablet), kanamycin (30μg / tablet), streptomycin (10μg / tablet), tetracycline (30μg / tablet), minocycline (30μg / tablet), doxycycline (30μg / tablet). 15 μg / tablet), erythromycin (15 μg / tablet), azithromycin (15 μg / tablet), norfloxacin (10 μg / tablet), ciprofloxacin (5 μg / tablet), levofloxacin (5 μg / tablet), lincomycin (2 μg / tablet), clindamycin (2 μg / tablet), vancomycin (30 μg / tablet), polymyxin B (300 μg / tablet), trimethoprim-sulfamethoxazole (25 μg / tablet), chloramphenicol (30 μg / tablet), florfenicol (30 μg / tablet), imipenem (10 μg / tablet).

[0030] UV-Vis spectrophotometer (model T3200), Shanghai Youke Instrument Co., Ltd.; ELISA analyzer (model DNM-9602), Beijing Pulang New Technology Co., Ltd.; Biosafety cabinet (model BSC-1500IIA2), Shanghai Boxun Medical Bio-Instrument Co., Ltd.; High-speed refrigerated centrifuge (model HT-TGL26), Hunan Kecheng Instrument Equipment Co., Ltd.

[0031] 1.1.2. Sample Source

[0032] In this embodiment, fecal samples from various animals at Tianjin Zoo were collected to isolate lactic acid bacteria (as shown in Table 1 below).

[0033] Table 1. Sources of lactic acid bacteria isolation

[0034]

[0035] 1.1.3.Strain

[0036] Salmonella enteritidis M265-2, Klebsiella pneumoniae 3097-4At, Staphylococcus aureus N2220-1At, Staphylococcus gallinarum N2596-1Yt, Pseudomonas aeruginosa 3102-3aT, and Escherichia coli 3100-1At were all obtained from Nanling Research Institute.

[0037] 1.2. Screening of Lactic Acid Bacteria

[0038] 1.2.1. Isolation and purification of lactic acid bacteria

[0039] Weigh 2g of sample and add it to 20mL of sterile MRS liquid medium, then incubate at 37℃ for 24h. Take the culture and serially dilute it to 10⁻⁸. Spread 100μL of the diluted culture onto MRS agar (containing 1% CaCO₃). After incubating each plate in an anaerobic environment at 37℃ for 48h, prioritize single colonies with fused calcium zones and inoculate them into MRS liquid medium, incubating anaerobically at 37℃ for 48h. Then, streak the culture onto MRS agar medium for strain purification. Repeat the strain purification process until a single strain is obtained.

[0040] 1.2.2. Determination of acid production capacity

[0041] The activated bacterial culture was inoculated into MRS liquid medium at a rate of 3% (v / v) and cultured at 37°C. Samples were taken at 0, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hours to determine the pH value of the culture medium. The MRS medium without bacterial inoculation was used as a blank control.

[0042] like Figure 1 As shown, the results indicated that 10 isolates lowered the pH of the culture medium to 3.7-4.1 after 48 hours, with strain 4434-3aT exhibiting the lowest pH at 3.7. Studies have shown a direct correlation between acid production capacity and probiotic properties; therefore, strains with a pH below 4.0 were initially selected: 4434-3aT, 4434-2aT, 4443-2AT, 4437-5aT, and 4437-4AT.

[0043] 1.2.3. Molecular biological identification

[0044] Five mL of bacterial culture was sent to Beijing Ruiboxingke Biotechnology Co., Ltd. PCR amplification of the bacterial culture was performed using the universal primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (5'-GGTTACCTTGTTACGACTT-3'). The amplified products were then bidirectionally sequenced. The assembled sequence based on the 16S rRNA sequencing results was compared with the BLAST sequence in the NCBI database.

[0045] The five selected bacterial strains were systematically identified using 16S rRNA gene sequencing, as shown in Table 2. Three strains were identified as *Lactobacillus reuteri* and two strains as *Lactobacillus johnsonii*, named *L. reuteri* 4434-3aT, *L. reuteri* 4434-2aT, *L. reuteri* 4443-2AT, *L. johnsonii* 4437-5aT, and *L. johnsonii* 4437-4AT, respectively, and will be further investigated in subsequent experiments.

[0046] Table 2. Results of strain identification

[0047]

[0048] Example 2. Determination of the in vitro hypoglycemic ability of lactic acid bacteria

[0049] 2.1. Determination of α-amylase inhibition rate

[0050] Following the method of Shukla et al., the fermentation supernatant was mixed with 1 mg / mL α-amylase solution at a volume ratio of 1:1 and incubated at 37°C for 10 min. Then, it was added to 500 µL of 1.5% (w / v) soluble starch solution and reacted at 37°C for 5 min. After that, 1 mL of 3,5-dinitrosalicylic acid solution was added and reacted in a boiling water bath for 5 min. After cooling to room temperature, 8 mL of PBS was added for dilution, and the absorbance was measured at 540 nm.

[0051]

[0052] In the formula: A represents the absorbance of lactic acid bacteria and α-amylase; B represents the absorbance of lactic acid bacteria without α-amylase; C represents the absorbance of lactic acid bacteria containing α-amylase but without lactic acid bacteria; D represents the absorbance without lactic acid bacteria and α-amylase.

[0053] The results are as follows Figure 2 As shown, all five lactic acid bacteria strains had the ability to inhibit α-amylase. Among them, L. reuteri 4434-3aT and L. johnsonii 4437-4AT had inhibition rates greater than or equal to 50%, namely 50.00±0.00% and 54.60±2.64%, respectively. L. johnsonii 4437-4AT showed the best inhibitory effect (P<0.05), followed by L. reuteri 4434-2aT.

[0054] 2.2. Determination of α-glucosidase inhibition rate

[0055] The method was followed as described by Hongyu W et al. The reaction mixture contained 25 μL of lactic acid bacteria suspension, 50 μL of pNPG solution (1.5 mmol / L), and 50 μL of PBS (0.1 mol / L, pH adjusted to 6.8). After thorough mixing, the mixture was incubated at 37°C for 10 min. At the end of the reaction, 30 μL of 0.2 U / mL α-glucosidase solution was added, and the reaction was continued at 37°C for 30 min. Finally, 50 μL of 0.2 mol / L Na₂CO₃ was added as a stop solution to stop the reaction. The values ​​were measured at 405 nm using a multi-mode microplate reader.

[0056]

[0057] In the formula: A represents the absorbance of lactic acid bacteria and α-glucosidase; B represents the absorbance of lactic acid bacteria without α-glucosidase; C represents the absorbance of α-glucosidase without lactic acid bacteria; D represents the absorbance of lactic acid bacteria without α-glucosidase.

[0058] like Figure 3As shown, the inhibition rates of the five lactic acid bacteria against α-glucosidase ranged from 46.77±3.36% to 14.61±4.16%. *L. johnsonii* 4437-5aT showed the best performance, but it was found to be difficult to activate during cultivation. While *L. johnsonii* 4437-4AT was slightly less effective, its inhibition rate reached 31.33±1.21%, demonstrating a significant advantage, and it did not exhibit the activation difficulties seen with *L. johnsonii* 4437-5aT. *L. reuteri* 4434-3aT showed the worst performance.

[0059] Therefore, based on the results of the in vitro hypoglycemic ability test of lactic acid bacteria, L. johnsonii 4437-4AT with the best overall performance and L. reuteri 4434-2aT with the second best performance were selected for further evaluation.

[0060] Example 3. Performance determination of lactic acid bacteria strains

[0061] 3.1. Determination of growth characteristics

[0062] After being removed from cryovials at -80°C, the strain was inoculated into MRS liquid medium and incubated at 37°C for 12 hours for recovery. The strain was inoculated into MRS liquid medium at a 3% (v / v) inoculum, with three replicates per strain, and incubated at 37°C. Samples were taken at 0, 2, 4, 6, 8, 10, 12, 24, 36, and 48 hours, and the OD values ​​of the culture medium were measured using a UV-Vis spectrophotometer. 600 The growth characteristics of the strains were analyzed and growth curves were plotted using MRS medium without inoculated strains as a blank.

[0063] like Figure 4 As shown, in the initial stage (around 0-10h), the growth rate of each strain was relatively fast, and the OD value rose rapidly; in the later stage (after 20h), they gradually entered the stable period, and the OD value remained basically stable; the final growth density of different strains (such as L. reuteri series and L. johnsonii series) was relatively similar.

[0064] 3.2. Determination of acid and bile salt resistance

[0065] Following the methods described in the literature, the activated strains (two generations) were first cultured anaerobically at 37°C for 20 h in MRS liquid medium, followed by centrifugation (5000 rpm, 4°C, 10 min). The bacterial cells were collected and washed twice with sterile PBS buffer. The supernatant was discarded, and the obtained bacterial cells were resuspended in sterile PBS solution and the OD600 was adjusted to 0.8 ± 0.05. Inoculum was then added at 2% (v / v) to MRS broth medium with pH adjusted to 2.0, 3.0, 0.1%, and 0.3% (w / v), respectively. The control group received unadjusted pH and bile-free MRS medium. After anaerobic incubation at 37°C for 4 h, the OD600 of the culture medium was measured. 600 For each strain, three parallel replicates were set up, with the culture medium of the uninoculated strain used as a reference. The growth ratio of the strain was calculated according to the following formula.

[0066] .

[0067] The OD600 values ​​of both strains increased after 4 h under different environments. If the OD600 value at 0 h is compared, the tolerance rate of the two strains may be greater than 100%. Therefore, this study chose to compare the OD600 value under normal growth environment.

[0068] like Figure 5 As shown in Figure A, the growth rate of L. johnsonii 4437-4AT is weak in a strongly acidic environment with pH=2.0.

[0069] like Figure 5 As shown in Figure B, the growth rate of L. johnsonii 4437-4AT was weak in an environment with pH=3.0.

[0070] like Figure 5 As shown in Figure C, L. johnsonii 4437-4AT had a higher growth rate in an environment with 0.1% bile salts.

[0071] like Figure 5 As shown in Figure D, L. johnsonii 4437-4AT exhibits weaker growth in an environment with 0.3% bile salts.

[0072] Therefore, in in vitro experiments, L. johnsonii 4437-4AT maintained a high survival rate under pH 2.0 and 0.3% bile salt conditions.

[0073] 3.3. Determination of antibacterial ability

[0074] The ability of the strain to inhibit pathogens was tested using a perforation method. Pathogens cultured to the logarithmic growth phase were diluted to 10⁻⁶. 8Antimicrobial inhibition tests were conducted using CFU / mL. Lactic acid bacteria were cultured to the logarithmic growth phase and then centrifuged (5000 rpm, 4℃, 10 min). The supernatant was filtered through a 0.22 μm filter membrane for later use. 100 μL of the pathogenic bacteria culture was evenly spread onto LB agar medium using a sterile cotton swab. A 1 mL sterile pipette tip was used to make a well in the medium, and 200 μL of the lactic acid bacteria supernatant was added to each well. Three replicates were set up for each strain, and the cultures were incubated at 37℃ for 24 h. The inhibition diameter was measured using calipers.

[0075] The results are shown in Table 4 below. Overall, L. johnsonii 4437-4AT showed more prominent antibacterial ability, with inhibition zone diameters ≥20mm against most pathogens (such as 3097-4At, N2220-1At, M265-2, and N2596-1Yt), while 4434-2aT had no inhibitory effect on N2220-1At and N2596-1Yt.

[0076] Therefore, L. johnsonii 4437-4AT has a more outstanding antibacterial ability and antibacterial spectrum, and is more suitable as a candidate probiotic for application scenarios such as food preservation and intestinal microecological regulation.

[0077] Table 4. Antibacterial activity of five lactic acid bacteria strains

[0078]

[0079] 3.4. Adhesion ability determination

[0080] 3.4.1. Surface hydrophobicity

[0081] Following the experimental method of Bilqeesa B et al., with slight modifications, the live lactic acid bacteria suspension was treated in the same manner as in Section 1.6. 1 mL of xylene was mixed with 3 mL of the adjusted cell suspension, allowed to stand at room temperature for 10 min, then vortexed for 2 min, and finally allowed to stand at room temperature for 4 h to separate into layers. The lower aqueous phase was carefully aspirated, and the OD was measured. 600 The hydrophobicity of each strain was calculated using the following formula, with three parallel replicates per strain.

[0082]

[0083] In the formula: At represents the initial OD600 value of the bacterial culture; A0 represents the OD600 value of the bacterial culture after 4 hours.

[0084] like Figure 6As shown, the hydrophobicity of the strains is: L. johnsonii 4437-4AT > L. reuteri 4434-2aT. This indicates a large difference in hydrophobicity among the strains. Since the surface hydrophobicity of lactic acid bacteria is positively correlated with their adhesion ability to the host intestinal mucosa, the high hydrophobicity of L. johnsonii 4437-4AT means that it is more likely to adhere to intestinal epithelial cells and has a stronger potential for colonization in the intestine.

[0085] 3.4.2. Self-aggregation ability

[0086] Following the experimental method of Ma et al., with slight modifications, the live lactic acid bacteria culture was treated as described above, then thoroughly vortexed to mix, and incubated at 37°C for 4 hours and 24 hours respectively, avoiding shaking. The supernatant was carefully aspirated, and the OD600 value (At) was measured. Three replicates were set up for each strain, and the autoagglutination rate of the strain was calculated according to the following formula.

[0087]

[0088] In the formula: At represents the initial OD600 value of the bacterial culture; A0 represents the OD600 values ​​of the bacterial culture after 4h and 24h.

[0089] like Figure 7 As shown, L. johnsonii 4437-4AT exhibits a high self-agglutination rate (around 60%), which is 1.5 times that of L. reuteri 4434-2aT. The self-agglutination ability of lactic acid bacteria is positively correlated with intestinal adhesion and biofilm formation. Strains with high self-agglutination rates (such as L. johnsonii 4437-4AT) are more likely to aggregate and colonize on the intestinal mucosa, and are also more conducive to exerting the physiological functions of probiotics.

[0090] 3.5. Antioxidant capacity determination

[0091] The activated strains were cultured in MRS broth at 37°C for 24 hours, centrifuged (10,000 rpm, 4°C, 5 min), and the supernatant was filtered through a 0.22 μm filter membrane for later use.

[0092] 3.5.1. Determination of total antioxidant capacity

[0093] The total antioxidant capacity (T-AOC) assay kit (FRAP method) from Solarbio Science & Technology Co., Ltd. was used according to the instructions for use. Three replicates were established to measure the total antioxidant capacity. The calculation formula is as follows:

[0094] Standard curve equation: 𝑦=8.8196𝑥−0.0036

[0095]

[0096] In the formula: 𝑦 represents the absorbance of the test group and the blank group at 593 nm; Vreaction total represents the total volume of the reaction (mL); Vsample represents the volume of the sample in the reaction (mL).

[0097] 3.5.2. DPPH scavenging ability determination

[0098] The DPPH scavenging ability assay kit (spectral method) was used according to the instructions. Three replicates were set up for each bacterial strain to determine its DPPH free radical scavenging ability. The calculation formula is as follows:

[0099]

[0100] In the formula: Ablank represents the absorbance of the blank group at 517 nm; Ameasurement represents the absorbance of the measurement tube at 517 nm; Acontrol represents the absorbance of the control group at 517 nm.

[0101] 3.5.3. Determination of hydroxyl radical scavenging ability

[0102] The antioxidant capacity of lactic acid bacteria was determined using the Regan hydroxyl radical scavenging assay kit. The experiment was conducted according to the kit's instructions, with three replicates. The hydroxyl radical scavenging capacity was measured. The calculation formula is as follows:

[0103]

[0104] In the formula: A1 represents the absorbance of the undamaged tube at 536 nm; A2 represents the absorbance of the damaged tube at 536 nm; A3 represents the absorbance of the measurement tube at 536 nm.

[0105] The results are shown in Table 6.

[0106] Table 6 Antioxidant capacity of lactic acid bacteria

[0107]

[0108] The table above shows that the comprehensive antioxidant capacity of L. johnsonii 4437-4AT lactic acid bacteria is strong in both "hydroxyl radical scavenging" and "DPPH scavenging".

[0109] 4.6. Drug resistance test

[0110] Antibiotic susceptibility testing was performed using the paper disc agar diffusion method, and the results were used to analyze the antibiotic susceptibility of each strain. The turbidity of the activated third-generation strains was adjusted with sterile PBS solution to match that of the turbidity test tube (0.5 McFarland units). The bacterial suspension was evenly spread onto MRS agar medium using a cotton swab, and antibiotic susceptibility discs were placed on the spread medium using sterile forceps. The medium was incubated at 37°C for 24 hours. The diameter of the inhibition zone was measured using calipers, and the susceptibility of the lactic acid bacteria strains to different antibiotics was determined according to CLSI standards. The results are shown in Table 7.

[0111] Table 7. Results of the susceptibility of lactic acid bacteria to different antibiotics.

[0112]

[0113] The function and effect of this embodiment:

[0114] Based on the above results regarding the in vitro hypoglycemic capacity, antibacterial activity, surface hydrophobicity, self-agglutination, and antioxidant properties of lactic acid bacteria, *L. johnsonii* 4437-4AT can be considered a versatile probiotic. It possesses strong stress resistance (acid and bile salt tolerance), high adhesion (hydrophobic surface, high self-agglutination rate), antibacterial / anti-colonization capabilities (large inhibition zone, high cross-agglutination rate with some pathogens), and outstanding performance in hydroxyl radical scavenging (antioxidant). These characteristics meet the core requirements for probiotics to colonize the host gut and exert their physiological functions. Furthermore, it exhibits optimal hypoglycemic performance and good inhibitory activity against α-glucosidase and α-amylase, making it suitable for intestinal regulation and blood sugar control.

[0115] The strain number of the above-mentioned lactic acid bacteria is 4437-4AT, which was deposited on January 20, 2026 at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67710.

Claims

1. A lactic acid bacterium with hypoglycemic function, characterized in that: The lactic acid bacteria was named Lactobacillus johnsonii 4437-4AT, strain number 4437-4AT, and was deposited on January 20, 2026 at the Guangdong Provincial Center for Microbial Culture Collection, located at 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession number GDMCC NO: 67710.

2. The application of the lactic acid bacteria as described in claim 1 in the preparation of hypoglycemic products.

3. The application of the lactic acid bacteria as described in claim 1 in the preparation of products that regulate the balance of human intestinal microecology.

4. A microbial preparation comprising the lactic acid bacteria of claim 1, the fermentation supernatant of lactic acid bacteria, the bacterial extract of lactic acid bacteria, or freeze-dried lactic acid bacteria powder.

5. The use of the microbial preparation of claim 4 in the preparation of functional products for inhibiting α-amylase and / or α-glucosidase.

6. The use of the microbial preparation as described in claim 4 in the preparation of foods, health products or drugs with the function of lowering blood sugar or assisting in regulating postprandial blood sugar.

Images